The N-methyl-D-aspartate antagonist CNS 1102 protects cerebral gray and white matter from ischemic injury following temporary focal ischemia in rats

Wolf-Rudiger Schabitz
Fuhai Li
Marc Fisher
University of Massachusetts Medical School

Follow this and additional works at: http://escholarship.umassmed.edu/oapubs
Part of the Life Sciences Commons, and the Medicine and Health Sciences Commons

Repository Citation
Schabitz, Wolf-Rudiger; Li, Fuhai; and Fisher, Marc, "The N-methyl-D-aspartate antagonist CNS 1102 protects cerebral gray and white matter from ischemic injury following temporary focal ischemia in rats" (2000). Open Access Articles. 1661.
http://escholarship.umassmed.edu/oapubs/1661

This material is brought to you by eScholarship@UMMS. It has been accepted for inclusion in Open Access Articles by an authorized administrator of eScholarship@UMMS. For more information, please contact Lisa.Palmer@umassmed.edu.
The N-Methyl-D-Aspartate Antagonist CNS 1102 Protects Cerebral Gray and White Matter From Ischemic Injury Following Temporary Focal Ischemia in Rats

Editorial Comment

Wolf-R. Schäbitz, Fuhai Li, Marc Fisher and Pak H. Chan

Stroke 2000;31:1709-1714

Stroke is published by the American Heart Association. 7272 Greenville Avenue, Dallas, TX 72514
Copyright © 2000 American Heart Association. All rights reserved. Print ISSN: 0039-2499. Online ISSN: 1524-4628

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://stroke.ahajournals.org/cgi/content/full/31/7/1709
The N-Methyl-D-Aspartate Antagonist CNS 1102 Protects Cerebral Gray and White Matter From Ischemic Injury Following Temporary Focal Ischemia in Rats

Wolf-R. Schäbitz, MD; Fuhai Li, MD; Marc Fisher, MD

Background and Purpose—Cerebral white matter is as sensitive as gray matter to ischemic injury and is probably amenable to pharmacological intervention. In this study we investigated whether an N-methyl-D-aspartate (NMDA) antagonist, CNS 1102, protects not only cerebral gray matter but also white matter from ischemic injury.

Methods—Ten rats underwent 15 minutes of temporary focal ischemia and were blindly assigned to CNS 1102 intravenous bolus injection (1.13 mg/kg) followed by intravenous infusion (0.33 mg/kg per hour) for 3.75 hours or to vehicle (n = 5 per group) immediately after reperfusion. Seventy-two hours after ischemia, the animals were perfusion fixed for histology. The severity of neuronal necrosis in the cortex and striatum was semiquantitatively analyzed. The Luxol fast blue–periodic acid Schiff stain and Bielschowsky’s silver stain were used to measure optical densities (ODs) of myelin and axons, respectively, in the internal capsule of both hemispheres, and the OD ratio was calculated to reflect the severity of white matter damage.

Results—Neuronal damage in both the cortex and the striatum was significantly better in the drug-treated group than in the placebo group (P < 0.05). The OD ratio of both the axons (0.93 ± 0.08 versus 0.61 ± 0.18; P < 0.01) and the myelin sheath (0.95 ± 0.07 versus 0.67 ± 0.19; P = 0.01) was significantly higher in the CNS 1102 group than in the placebo group. The neurological score was significantly improved in the drug-treated group (P < 0.05).

Conclusions—The NMDA receptor antagonist CNS 1102 protects not only cerebral gray matter but also white matter from ischemic injury, most probably by preventing degeneration of white matter structures such as myelin and axons. (Stroke. 2000;31:1709-1714.)

Key Words: cerebral ischemia, focal ▪ middle cerebral artery occlusion ▪ N-methyl-D-aspartate ▪ white matter ▪ rats

A cute central nervous system injuries such as ischemic stroke are accompanied by a marked elevation in the extracellular glutamate concentration.1 Toxic activation of glutamate receptors, or excitotoxicity, is an important trigger of neuronal death.2 Glutamate-triggered Ca2+ influx can be specifically blocked by antagonists of the receptor-mediated, Ca2+-conducting N-methyl-D-aspartate (NMDA) channels that are predominantly on neurons. NMDA receptor antagonists such as MK 801 or CNS 1102 (Cerestat) protect gray matter from ischemic injury.3–6 Cerebral white matter was shown to be sensitive to acute ischemia and can probably be protected by pharmacological intervention.7 In contrast to gray matter, glutamate is not thought to play an important role in white matter ischemic injury.5,9 As suggested by in vitro studies, Ca2+ overload in ischemic axons is related to activation of Na+ channels rather than a function of a glutamate receptor stimulation.9 Clinically, it is important to understand and treat white matter ischemic changes that are common in the elderly. To our knowledge, no in vivo studies exist concerning pharmacological protection of cerebral white matter changes after cerebral ischemia. In this study we investigated whether pharmacological intervention with a potent neuroprotectant, the noncompetitive NMDA antagonist CNS 1102, could be used to protect white matter structures after focal cerebral ischemia.

Materials and Methods
All procedures were approved by our institutional Animal Research Committee. In 10 male Sprague-Dawley rats weighing 300 to 350 g, 15 minutes of temporary focal cerebral ischemia was induced by the intraluminal suture occlusion method. All experiments were performed in a blinded manner. Nonfasted animals were randomly assigned before surgery to receive CNS 1102 dissolved in saline (n = 5) or the same amount of vehicle (n = 5).

The animals were intraperitoneally anesthetized with chloral hydrate (400 mg/kg body wt). The left femoral artery was cannulated with PE-50 polyethylene tubing for continuous monitoring of arterial blood pressure and blood sampling for analysis of blood gases. Measurements were recorded before surgery and 30 and 180 minutes after ischemic onset. Rectal temperature was maintained during...
surgery at 37°C with a feedback-regulated heating lamp. The right middle cerebral artery was occluded via a transluminal approach, as previously described.\textsuperscript{10,11} Briefly, the right common carotid artery and the right external carotid artery were exposed through a midline neck incision. The proximal portions of the common carotid artery and the external carotid artery were first ligated with a 3-0 silk suture just distal to the arteriotomy. To prevent bleeding, the common carotid artery was loosely ligated with a 3-0 silk suture and then coated with silicon (Bayer), was inserted through an arteriectomy of the common carotid artery, and the posterior communicating artery. Positioned approximately 17 mm from the bifurcation, the tip of the silicon (Bayer), was inserted through an arteriectomy of the common carotid artery and the external carotid artery were first ligated with a 3-0 silk suture just distal to the arteriotomy.

An intravenous bolus injection of the drug (1.13 mg/kg in saline) or the vehicle (saline) was started immediately after reperfusion (15 minutes after vessel occlusion), followed by a continuously intravenous infusion for 3.75 hours at a dose of 0.33 mg/kg per hour of CNS 1102 or physiological saline. CNS 1102 has a half-life of 63 minutes, is lipophilic, and easily crosses the blood-brain barrier, like most other noncompetitive NMDA antagonists.\textsuperscript{4} The chemical structure of CNS 1102 was reported in a previous study.\textsuperscript{4} After discontinuation of the infusion, the animals were allowed to recover from the anesthesia and were neurologically scored with a 5-point scale: 0, no neurological deficit; 1, failure to extert left forepaw fully; 2, circling to the left; 3, falling to the left; and 4, no spontaneous walking with a depressed level of consciousness.

Physiological variables, presented in the Table, showed no significant differences between the 2 groups (P>0.05). The percent body weight decline did not differ between the 2 groups (15.3% versus 13.4%). The neurological score at day 4 was significantly worse in the placebo than in the CNS 1102–treated group (1.0±0.5 versus 0.4±0.3; P<0.05).

The histopathological analysis revealed that 3 of the 5 rats in the placebo group had widespread neuronal necrosis in both the cortex and striatum, and 2 other rats had SNN in the striatum and individual neuronal necrosis or SNN in the frontoparietal cortex. These changes were accompanied by
astrogliosis and microglia activation. In the CNS 1102–treated rats, 2 rats showed normal cerebral gray matter, 1 had individual neuronal necrosis only in the striatum, and 2 other animals demonstrated SNN in the striatum and individual neuronal death in the cortex. Overall statistical analysis revealed that both cortical and striatal neuronal damage in the CNS 1102–treated group were significantly better than in the placebo group (P<0.05), as shown in Figure 1.

Representative photomicrographs chosen from the internal capsule from both groups are shown in Figure 2. White matter in the 2 control animals that had SNN in the gray matter appeared vacuolated. The myelin sheaths and axons were moderately damaged. A moderate astrocytic reaction with increased GFAP immunoreactivity and a few microglia occurred in the same area. Oligodendrocytes proliferated in the periphery of the white matter lesion. Three other animals in the control group that had severe ischemic lesions also developed severe white matter damage. Myelin sheaths lost their LFB-PAS stainability and appeared as empty spaces (vacuoles) separating myelin sheaths in the lesion areas of white matter (Figure 2B and 2E). Axons appeared as irregular, twisted profiles and showed segmental fragmentation with Bielschowsky’s stain (Figure 2H). Increased cellular reactions occurred in the injured white matter that included inflammatory cells, in particular macrophages. Hypertrophied astrocytes with strong GFAP immunoreactivity and activated microglia were found in the lesion area. In the CNS 1102–treated group, 3 rats with essentially normal gray matter occurred in the same area. Oligodendrocytes proliferated in the periphery of the white matter lesion. Three other animals in the CNS 1102–treated group showed normal cerebral gray matter, 1 had SNN in the striatum with selective neuronal necrosis in the cortex. Overall statistical analysis demonstrated that axonal injury in cerebral white matter (OD ratio: 0.93±0.08 in the CNS 1102–treated group versus 0.61±0.18 in the placebo group; P<0.01) and damage to the myelin sheath (OD ratio: 0.95±0.07 in the CNS 1102–treated group versus 0.67±0.19 in the placebo group; P=0.01) was significantly reduced by CNS 1102 treatment (Figure 3).

Discussion

This study demonstrates that a noncompetitive NMDA receptor antagonist, CNS 1102, protects cortical and striatal neurons from ischemic injury and significantly reduces ischemic damage in white matter structures such as myelin and axons. This qualitative observation of reduced white matter injury should, in the future, be confirmed by a more quantitative approach such as a Western blot analysis of axonal and myelin injury. Clinically, CNS 1102 improved the neurological outcome. No significant difference in physiological parameters and weight loss was observed between the 2 groups during the experiment as it has been reported by other investigators.4,5

Cerebral ischemia triggers an excessive release of glutamate, producing overstimulation of glutamate receptors, especially the NMDA receptor. The subsequent cellular Ca2+ overload is generally thought to represent the “final common pathway,” leading to necrotic cell death of neurons.13 NMDA antagonists that prevent the Ca2+ influx through NMDA receptor blockade of Ca2+ channels have successfully been used to treat neuronal injury after experimental ischemia in vivo.1–6 CNS 1102 (Cerestat) in particular is a well-investigated NMDA antagonist that has potent neuroprotective effects.6 CNS 1102 in this study protected striatal and cortical neurons from temporary focal cerebral ischemia. Similar results have been reported on ischemic lesion size with the use of the same dose after permanent and temporary focal cerebral ischemia.4,5

The main novel finding in this study is that CNS 1102 protects white matter structures such as axons and myelin from ischemic injury. This finding is of importance because it demonstrates that white matter damage after ischemia may be treatable and could be of particular clinical interest for the future treatment of lacunar strokes. Although studies have demonstrated that white matter is susceptible to ischemic injury, the mechanisms of white matter injury are not well characterized.7,14 In contrast to gray matter ischemia, in vitro studies suggest that activation of glutamate receptors may not be a key event in the mediation of ischemic cerebral white matter injury. Recent studies suggested some possible explanations for ischemic white matter injury.8 First, the Na+/K+-ATPase of CNS axons fails after ischemia, leading to accumulation of axoplasmatic Na+ through noninactivating Na+ channels. Coupled with severe K+ depletion that results in large membrane depolarization, high intracellular Na+ stimulates the reverse operation of Na+–Ca2+ exchanger, causing axonal Ca2+ overload that results in white matter injury by activating Ca2+-dependent enzymes.8,9 Accumulation of intracellular Ca2+ and subsequent damage to the myelin sheath can also occur through reversal of the electrogenic Na+/K+-glutamate transporter after axonal depolarization.8,15 Second, oligodendrocytes that myelinate the axon can be damaged in vitro by glutamate exposure, which does not appear to involve glutamate receptor activation.16 Third, α-amino-3-hydroxy-5-methyl-4-isoxasole propionic acid (AMPA)/kainate seems to be more toxic to oligodendrocytes. It has been shown that oligodendrocytes contain the AMPA receptor and can be damaged in vivo by AMPA or kainate.17 Lastly, degeneration secondary to gray matter damage, so-called Wallerian degeneration, may be another important contributor to white matter injury. Excitotoxic lesions in the thalamus or basal ganglia have been shown experimentally to secondarily damage white matter structures such as the myelin and axon within 2 to 4 days.18 White matter damage observed in the present study may be related to Wallerian degeneration because survival time in our study was within this time frame (3 days), and the gray matter lesion was primarily in the striatum with selective neuronal necrosis in the cortex.

On the basis of the mechanisms of white matter injury described above, protection of white matter from ischemic injury may be obtained by blocking Na+ channel,4 reducing Ca2+ load,8 inhibiting AMPA receptors,8,17 or protecting gray matter.8 The protective effect of ketamine, an NMDA receptor antagonist, on anoxic optic nerve was previously reported and was supposed to be related to its blocking voltage-gated Na+ channels.19 Interestingly, an NMDA receptor antagonist was demonstrated to protect the spinal cord from ischemic injury.20 It is not known whether the NMDA antagonist...
exerted its action on spinal gray matter or white matter. It seems unlikely that the protective affect of NMDA receptor antagonists on white matter is mediated by direct NMDA receptor, since neither the axon nor the myelin has been proven to contain NMDA receptors. The most plausible mechanism of the neuroprotective effect of CNS 1102 in the present study is likely a secondary prevention of white matter damage by neuroprotection of cerebral gray matter. Clearly, further studies will be needed to elucidate how NMDA receptor antagonists protect white matter from ischemic injury.

In this study white matter damage was induced with the intraluminal suture occlusion model. The short occlusion time was chosen to provide demonstrable white matter damage, to keep gray matter damage minimal, and to guarantee a long survival time. However, to further understand white matter damage in vivo and to explore how drugs protect white matter in vivo, an animal model of pure white matter ischemia would be useful. This is thus far not available for both technical and pathophysiological reasons.

In conclusion, the present study suggests that besides the previously known protective effects of this NMDA antagonist, additional protection of white matter structures such as myelin and axons after focal cerebral ischemia does occur. The role of NMDA antagonists in protecting white matter from ischemic injury needs further clarification. The study of in vivo white matter injury after focal ischemia is of particular clinical relevance because of the prevalence of lacunar strokes.

Acknowledgments
This study was supported by the Harrington Neurological Research Fund. We thank Dr. Kai-Feng Liu of Henry Ford Hospital, Detroit, Mich, for her help with the histology study.

References
Editorial Comment

During the past 2 decades, basic and preclinical studies have demonstrated the significant involvement of glutamate neurotoxicity in neuronal death and infarction after cerebral ischemia. Despite this understanding, clinical trials that used neuroprotective agents which targeted glutamate neurotoxicity and other biochemical cascades involved in neuronal death have failed.\(^1\) It is suggested that alternative and/or new therapeutic strategies are needed. One possible strategy is to protect white matter from ischemic injury. In this article, Schäbitz and colleagues have provided intriguing results which demonstrate that an NMDA antagonist protects both cerebral gray and white matter from ischemic injury after temporary focal ischemia in rats. This is a somewhat surprising but novel finding, since it is known that the axons and myelin sheaths may not contain NMDA receptors. Nevertheless, the authors have provided some plausible explanations for their observations. Because white matter oligodendrocytes are known to be vulnerable to AMPA/kainate receptor-mediated excitotoxicity,\(^2\) the possible AMPA/kainate receptor agonist property of this drug needs further evaluation. This study provides an impetus for additional therapeutic studies that will target the white matter after transient focal cerebral ischemia.\(^3\)

Pak H. Chan, PhD, Guest Editor
Neurosurgical Laboratories
Stanford University
Palo Alto, California

References